Opus Genetics Price to Free Cash Flow Ratio 2010-2024 | IRD

Opus Genetics price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as

Opus Genetics Price to Free Cash Flow Ratio 2010-2024 | IRD

Opus Genetics price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$169.8B
Vertex Pharmaceuticals (VRTX)$121.4B
Gilead Sciences (GILD)$109.7B
Bristol Myers Squibb (BMY)$106.4B
Regeneron Pharmaceuticals (REGN)$102.2B
CSL (CSLLY)$92.8B
GSK (GSK)$79.1B
Alnylam Pharmaceuticals (ALNY)$36.5B
Argenex SE (ARGX)$33.1B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$26.7B
Illumina (ILMN)$23.3B
Moderna (MRNA)$21.2B
BeiGene (BGNE)$21.1B
Genmab (GMAB)$15.3B
Incyte (INCY)$14.2B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$12.9B
Sarepta Therapeutics (SRPT)$12.4B
Insmed (INSM)$12.2B
Vaxcyte (PCVX)$11.8B
Bio-Techne Corp (TECH)$11.2B
QIAGEN (QGEN)$9.5B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.6B
Revolution Medicines (RVMD)$8.4B
Legend Biotech (LEGN)$8.3B
Exelixis (EXEL)$8.2B
Viking Therapeutics (VKTX)$8.2B
Intra-Cellular Therapies (ITCI)$8.1B